Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donor Lymphocyte Infusion (Thomas Jefferson University)
- Development stage
- Unknown
- Lead developer
- Thomas Jefferson University
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Donor lymphocyte infusion (DLI) is an adoptive cell therapy used in the context of allogeneic hematopoietic stem cell transplantation (HSCT). In the specific "Two-Step" reduced-intensity conditioning (RIC) protocol developed at the Sidney Kimmel Cancer Center at Thomas Jefferson University, DLI is administered following a conditioning regimen of fludarabine, thiotepa, and total body irradiation (TBI). This is followed by the administration of melphalan to induce T-cell tolerization, which aims to prevent graft-versus-host disease (GVHD) while preserving the graft-versus-leukemia (GVL) effect. This approach is being evaluated for high-risk hematologic malignancies, including acute leukemia, myelodysplastic syndromes, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia.
- Other names
- DLIDonor T-cell infusionJefferson Two-Step DLIdonor lymphocyte infusion-Sidney Kimmel Cancer Center at Thomas Jefferson University-acute leukemia-myelodysplastic syndromes-Hodgkin's lymphoma-non-Hodgkin's lymphoma-multiple myeloma-chronic myeloid leukemia
02
Targets
MICB (Major histocompatibility complex class i-related protein B)HLA-A (HLA class I histocompatibility antigen A alpha chain)MiHA (Minor histocompatibility antigen)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on Donor Lymphocyte Infusion (Thomas Jefferson University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Donor Lymphocyte Infusion (Thomas Jefferson University).